scholarly journals Advances in the Application of Nanomaterials as Treatments for Bacterial Infectious Diseases

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1913
Author(s):  
Yuan-Pin Hung ◽  
Yu-Fon Chen ◽  
Pei-Jane Tsai ◽  
I-Hsiu Huang ◽  
Wen-Chien Ko ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Wound Repair ◽  
Antimicrobial Agents ◽  
Bacterial Colonization ◽  
Diagnosis And Treatment ◽  
Antigenic Protein ◽  
Humoral And Cellular Immunity ◽  
Low Toxicity ◽  
Encapsulation Methods ◽  
Antibacterial Capacity

Bacteria-targeting nanomaterials have been widely used in the diagnosis and treatment of bacterial infectious diseases. These nanomaterials show great potential as antimicrobial agents due to their broad-spectrum antibacterial capacity and relatively low toxicity. Recently, nanomaterials have improved the accurate detection of pathogens, provided therapeutic strategies against nosocomial infections and facilitated the delivery of antigenic protein vaccines that induce humoral and cellular immunity. Biomaterial implants, which have traditionally been hindered by bacterial colonization, benefit from their ability to prevent bacteria from forming biofilms and spreading into adjacent tissues. Wound repair is improving in terms of both the function and prevention of bacterial infection, as we tailor nanomaterials to their needs, select encapsulation methods and materials, incorporate activation systems and add immune-activating adjuvants. Recent years have produced numerous advances in their antibacterial applications, but even further expansion in the diagnosis and treatment of infectious diseases is expected in the future.

2015 Nelson's Pediatric Antimicrobial Therapy

2015 ◽  
Keyword(s):  
Health Care ◽  
Infectious Diseases ◽  
Health Care Providers ◽  
Antimicrobial Therapy ◽  
Antimicrobial Agents ◽  
Complete Information ◽  
Care Providers ◽  
Dosing Regimens

New! This bestselling and widely used resource on pediatric antimicrobial therapy provides instant access to reliable, up-to-the-minute recommendations for treatment of all infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today, and include complete information about dosing regimens. In response to growing concerns about overuse of antibiotics, the book includes guidelines on when not to prescribe antimicrobials. Key 21st edition features! Contents

scholarly journals Light and Phages on Tackle of Infectious Diseases

2021 ◽  
Author(s):  
Felipe de Paula Nogueira Cruz ◽  
Andréa Cristina Bogas ◽  
Cristina Paiva de Sousa
Keyword(s):  
Infectious Diseases ◽  
Antimicrobial Agents ◽  
Microbial Inactivation ◽  
Resistant Bacteria ◽  
Bacteriophage Therapy ◽  
Drug Resistant Bacteria ◽  
Evolutionary Trajectories ◽  
Efficient Alternative ◽  
Emergence Of Resistance ◽  
Inducing Resistance

There has been an important increase in the emergence of resistance in microbial population worldwide. This trajectory needs, necessarily new approaches to treat infectious diseases. The ability to detect and prevent the evolutionary trajectories of microbial resistance would be of value. Photodynamic inactivation (PDI) represents an efficient alternative treatment for diseases caused by viruses, which can cause infections well documented in various mammals. PDI can kill cells after exposure with the appropriate photosensitizer (PS), light of adequate wavelength combined with the presence of oxygen, without inducing resistance. Cytotoxic reactive species formed interaction with vital biomolecules leading to irreversible microbial inactivation. Bacteriophages can act on delivering antimicrobial agents into bacteria, which consist in a likely instrument for the treatment of infectious diseases. Non-enveloped bacteriophages are more difficult to tolerate photoinactivation than enveloped phages, which makes them an important model tool to evaluate the efficiency of PDI therapy against viruses that cause diseases in humans. Combination of photosensitizers and bacteriophage therapy can be employed to eradicate biofilms, contributing to control of infections also caused by drug-resistant bacteria.

scholarly journals The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19

mBio ◽  
2021 ◽  
Vol 12 (2) ◽  
Author(s):  
Arturo Casadevall ◽  
Liise-anne Pirofski ◽  
Michael J. Joyner
Keyword(s):  
Infectious Diseases ◽  
Antimicrobial Agents ◽  
Severe Disease ◽  
Antibody Therapy ◽  
Course Of Disease ◽  
Medical Practitioners ◽  
History Of ◽  
Serum Therapy ◽  
Effective Lessons ◽  
Further Development

ABSTRACT Antibody therapies such as convalescent plasma and monoclonal antibodies have emerged as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins differ from conventional antimicrobial agents in that they mediate direct and indirect antimicrobial effects that work in concert with other components of the immune system. The field of infectious diseases pioneered antibody therapies in the first half of the 20th century but largely abandoned them with the arrival of conventional antimicrobial therapy. Consequently, much of the knowledge gained from the historical development and use of immunoglobulins such as serum and convalescent antibody therapies was forgotten; principles and practice governing their use were not taught to new generations of medical practitioners, and further development of this modality stalled. This became apparent during the COVID-19 pandemic in the spring of 2020 when convalescent plasma was initially deployed as salvage therapy in patients with severe disease. In retrospect, this was a stage of disease when it was less likely to be effective. Lessons of the past tell us that antibody therapy is most likely to be effective when used early in respiratory diseases. This article puts forth three principles of antibody therapy, namely, specificity, temporal, and quantitative principles, connoting that antibody efficacy requires the administration of specific antibody, given early in course of disease in sufficient amount. These principles are traced to the history of serum therapy for infectious diseases. The application of the specificity, temporal, and quantitative principles to COVID-19 is discussed in the context of current use of antibody therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Functions and potential of lipocalin-2 as fecal biomarker for acute gastrointestinal infections (review of literature)

2021 ◽  
Vol 66 (6) ◽  
pp. 371-373
Author(s):  
Ekaterina Dmitrievna Lyutsova ◽  
M. D. Gospodinova ◽  
Y. D. Bocheva
Keyword(s):  
Infectious Diseases ◽  
Structure Function ◽  
Acute Diarrhea ◽  
Morbidity And Mortality ◽  
Diagnosis And Treatment ◽  
Lipocalin 2 ◽  
Review Of Literature ◽  
Gastrointestinal Infections ◽  
Non Invasive ◽  
Intestinal Infections

Despite the visible progress in reducing morbidity and mortality from intestinal infections and acute diarrhea associated with them, especially in childhood, the problem of their diagnosis and treatment remains relevant. The article discusses the structure, function and application of lipocalin-2 in infectious diseases as a non-invasive biomarker of bacterial inflammation in the intestine.

Report of the Task Force on Diagnosis and Management of Meningitis

PEDIATRICS ◽  
1986 ◽  
Vol 78 (5) ◽  
pp. 959-982
Author(s):  
Jerome O. Klein ◽  
Ralph D. Feigin ◽  
George H. McCracken
Keyword(s):  
Bacterial Meningitis ◽  
American Academy ◽  
Antimicrobial Agents ◽  
Task Force ◽  
Diagnosis And Treatment ◽  
Diagnosis And Management ◽  
Treatment And Prevention ◽  
American Academy Of Pediatrics ◽  
Early Signs ◽  
Neurologic Sequelae

Children still die or suffer permanent neurologic sequelae as a result of bacterial meningitis. Prompt diagnosis and aggressive management are the goals, but early signs of meningitis are often subtle and nonspecific and, therefore, may be recognized only in retrospect. The physician must identify among the many febrile children seen every day in office practice—most of whom have spontaneously resolving illnesses usually caused by viruses—the few children who have serious bacterial infection requiring early intervention. No single test or battery of tests replaces the clinical acumen of the physician in identifying the child with early signs of bacterial meningitis. Because of controversies about diagnosis and treatment of meningitis voiced in various forums, including the courtroom, the Task Force on Diagnosis and Management of Meningitis has been asked by the Executive Board of the American Academy of Pediatrics to prepare a report on the causes, diagnosis, management, and outcome of meningitis in infants and children. This task force selected for discussion issues of current relevance and controversy in the diagnosis and treatment of bacterial and nonbacterial meningitis. Many other aspects of meningitis are discussed elsewhere. Commentaries on the prevention of disease by chemoprophylaxis (antimicrobial agents) or immunoprophylaxis (vaccines) have been prepared by the Committee on Infectious Diseases of the American Academy of Pediatrics. In addition the Morbidity and Mortality Weekly Report (Centers for Disease Control, Atlanta) publishes recommendations on vaccine usage and chemoprophylaxis formulated by the Advisory Committee on Immunization Practices. These resources are of value to the practitioner who cares for children and needs information on optimal measures for the treatment and prevention of meningitis.

Sign in / Sign up

Export Citation Format

Share Document